|Bid||247.75 x 1100|
|Ask||249.36 x 900|
|Day's range||247.88 - 251.05|
|52-week range||198.64 - 258.45|
|Beta (5Y monthly)||0.58|
|PE ratio (TTM)||24.61|
|Earnings date||01 Aug 2022 - 05 Aug 2022|
|Forward dividend & yield||7.76 (3.14%)|
|Ex-dividend date||16 May 2022|
|1y target est||249.62|
Novartis (NVS) Cosentyx gets a positive CHMP recommendation for the indication of juvenile idiopathic arthritis.
J&J's immunology mega-blockbuster loses exclusivity in the U.S. next year -- and Amgen's biosimilar is ready to capitalize.
Mirati (MRTX) seeks a nod for its lung cancer candidate adagrasib in the European Union. A regulatory filing in the United States is currently under the FDA review with decision pending this year-end.